Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley

Atai Beckley N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments, has announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech Limited in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.

Latham & Watkins LLP represented atai Life Sciences in the transaction with a corporate team led by New York partner Nathan Ajiashvili, London partner Robbie McLaren, and Orange County partners Scott Shean and Brian Umanoff, with associates Samantha Peacock, Abby Timmons, Richard Dodding, Kaj Nielsen, Christopher Siino, Adam Picker, Elana Cates, and Chloe Barr. Advice was also provided on executive compensation and employee benefits matters by London partner Sarah Gadd, Washington, D.C. partner David Della Rocca, with associate Venice Ma; and on public company matters by New York counsel Irina Yevmenenko, with associate Catriela Cohen.